55 completed, 15 terminated, 7 unknown, 5 recruiting. 88 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 88 | Completed 55, Terminated 15, Unknown 7, Recruiting 5, Active not recruiting 3, Withdrawn 2, Not yet recruiting 1 |
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iron Repletion in Cystic Fibrosis IV Repletion, PO Repletion - Cystic Fibrosis, Iron Deficiencies | Phase 4 | Not yet recruiting | University of Michigan | 100 | 2026-11-01 | 2026-10-29 |
| Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Elexacaftor, Tezacaftor, Ivacaftor, Ivacaftor (VX-770) - Cystic Fibrosis (CF) | Phase 4 | Recruiting | Istituto Giannina Gaslini | 50 | 2026-09-18 | 2026-10-14 |
| Ensuring Access to Optimal Therapy in CF: The ENACT Study Elexacaftor / Ivacaftor / Tezacaftor, therapeutic drug monitoring - Cystic Fibrosis (CF) | Phase 4 | Recruiting | Arkansas Children's Hospital Research Institute | 100 | 2025-06-10 | 2026-06-02 |
| Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy Discontinuation of Pancreatic Enzyme Replacement Therapy - Cystic Fibrosis (CF), Pancreatic Insufficiency | Phase 4 | Completed | Indiana University | 17 | 2024-12-03 | 2026-07-02 |
| Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis Ceftolozane/tazobactam - Bronchiectasis, Cystic Fibrosis | Phase 4 | Unknown | Sunshine Coast Hospital and Health Service | 30 | 2023-10-01 | 2023-09-13 |
| Estrogen Supplementation and Bone Health in Women With CF Transdermal estrogen, Progesterone - Cystic Fibrosis, Hypoestrogenism | Phase 4 | Recruiting | Johns Hopkins University | 75 | 2023-05-02 | 2025-11-14 |
| Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study Beta-lactam antibiotic, Aminoglycoside - Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation | Phase 4 | Recruiting | Chris Goss | 730 | 2023-04-23 | 2026-07-08 |
| Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis Mannitol Inhalant Product - Cystic Fibrosis | Phase 4 | Completed | University of North Carolina, Chapel Hill | 14 | 2023-03-28 | 2026-01-07 |
| Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis Imipenem/Cilastatin/Relebactam - Cystic Fibrosis, Pneumonia, Bacterial | Phase 4 | Terminated | Hartford Hospital | 4 | 2023-01-03 | 2024-12-17 |
| Efficacy of Intensive Cholecalciferol Monitoring and Supplementation on Serum vitD Levels in Pediatric Patients With CF Cholecalciferol Pill - Vitamin D Deficiency, Cystic Fibrosis | Phase 4 | Completed | Hospital Infantil de Mexico Federico Gomez | 40 | 2022-06-22 | 2025-04-08 |
| Cefiderocol Pharmacokinetics in Adult Patients With Cystic Fibrosis Cefiderocol - Cystic Fibrosis, Pneumonia, Bacterial | Phase 4 | Completed | Hartford Hospital | 10 | 2022-06-01 | 2024-12-16 |
| BEGIN Novel ImagiNG Biomarkers 129Xe - Cystic Fibrosis | Phase 4 | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 19 | 2022-05-01 | 2026-09-22 |
| Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon CREON - Cystic Fibrosis, Chronic Pancreatitis | Phase 4 | Completed | AbbVie | 30 | 2021-10-14 | 2024-07-23 |
| Markers of Osteoporosis in Cystic Fibrosis Denosumab - Cystic Fibrosis | Phase 4 | Recruiting | University of Texas Southwestern Medical Center | 100 | 2021-09-02 | 2026-05-05 |
| Pharmacokinetics of Omadacycline in Cystic Fibrosis Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet [Nuzyra] - Cystic Fibrosis | Phase 4 | Completed | Paul Beringer | 9 | 2021-07-01 | 2026-05-08 |
| Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis Rifampin - Cystic Fibrosis, MRSA | Phase 4 | Withdrawn | Johns Hopkins University | 2020-12-01 | 2021-01-14 | |
| Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis Initiation of CFTR Modulator, Hyperpolarized Xenon 129 - Cystic Fibrosis | Phase 4 | Active not recruiting | Children's Hospital Medical Center, Cincinnati | 26 | 2020-11-15 | 2026-01-28 |
| Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Elexacaftor/Tezacaftor/Ivacaftor - Cystic Fibrosis, Cystic Fibrosis Liver Disease | Phase 4 | Active not recruiting | Royal College of Surgeons, Ireland | 206 | 2020-09-03 | 2026-09-09 |
| Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis Vitamin D3, Placebo vitamin D3, Inulin - Cystic Fibrosis, Dysbiosis | Phase 4 | Completed | Emory University | 40 | 2020-03-13 | 2024-02-07 |
| Hyperpolarized Imaging for New Treatments Initiation of CFTR Modulator - Cystic Fibrosis | Phase 4 | Completed | Children's Hospital Medical Center, Cincinnati | 47 | 2020-01-13 | 2026-10-07 |
Showing 20 of 88. Sign in to see all of them.
Exocrine Pancreatic Insufficiency (9) · Pseudomonas Infections (9) · Bone Diseases, Metabolic (3) · Osteoporosis (3) · Lung Diseases (2) · Malnutrition (2) · Pancreatitis, Chronic (2) · Pneumonia (2) · Pneumonia, Bacterial (2) · Anemia, Iron-Deficiency (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Avitaminosis (1) · Bone Diseases (1) · Bronchiectasis (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (88) · Digestive System Diseases (88) · Genetic Diseases, Inborn (88) · Infant, Newborn, Diseases (88) · Pancreatic Diseases (87) · Respiratory Tract Diseases (87) · Lung Diseases (86) · Bacterial Infections and Mycoses (12) · Infections (12) · Bacterial Infections (11) · Nutritional and Metabolic Diseases (10) · Gram-Negative Bacterial Infections (9) · Metabolic Diseases (8) · Pathological Conditions, Signs and Symptoms (7) · Pathologic Processes (5)
Pancrelipase (5) · dornase alfa (5) · Azithromycin (4) · ivacaftor (4) · Cholecalciferol (3) · Tobramycin (3) · elexacaftor, ivacaftor, tezacaftor drug combination (3) · lumacaftor, ivacaftor drug combination (3) · Alendronate (2) · Ceftazidime (2) · Itraconazole (2) · Meropenem (2) · ataluren (2) · ceftolozane, tazobactam drug combination (2) · tezacaftor, ivacaftor drug combination (2)
Novartis Pharmaceuticals (6) · Children's Hospital Medical Center, Cincinnati (3) · Forest Laboratories (3) · Genentech, Inc. (3) · University of Alabama at Birmingham (3) · University of Southern California (3) · AbbVie (2) · Assistance Publique - Hôpitaux de Paris (2) · Chris Goss (2) · Emory University (2) · Hartford Hospital (2) · Johns Hopkins University (2) · Joseph L. Kuti, PharmD (2) · The Alfred (2) · Vertex Pharmaceuticals Incorporated (2)
United States (46) · Canada (10) · United Kingdom (9) · Italy (7) · France (6) · Germany (5) · Australia (4) · Belgium (4) · Spain (4) · Czechia (2) · Hungary (2) · Ireland (2) · Mexico (2) · Poland (2) · Argentina (1)
Jason Woods, PhD (3) · Joseph L Kuti, PharmD (3) · Felix Ratjen, MD (2) · Michelle Freemer, M.D. (2) · Patrick Flume, MD (2) · Steven M Rowe, MD (2) · Adelaida Lamas, MD (1) · Adriana Franzese, Dr (1) · Adupa P Rao, M.D. (1) · Alan Smyth (1) · Alexandra Papaioannou, M.D. (1) · Andreas Freitag, M.D. (1)
PMID 33735508, PMID 36625789, PMID 12791627, PMID 12804435, PMID 14717616, PMID 15319624, PMID 1550069, PMID 16123520, PMID 16627012, PMID 18641106, PMID 19821321, PMID 20442386, PMID 20507651, PMID 20693248, PMID 22024822, PMID 22399505, PMID 22506011, PMID 22563440, PMID 22595153, PMID 22746323, PMID 22805498, PMID 24121143, PMID 24891257, PMID 24950362, PMID 25921451, PMID 26282839, PMID 26302738, PMID 26416780, PMID 26830335, PMID 26903303, PMID 27144634, PMID 27313953, PMID 27435882, PMID 27550351, PMID 28611235, PMID 28614995, PMID 28784670, PMID 28986022, PMID 31685468, PMID 32532226, PMID 33358119, PMID 33358691, PMID 34159577, PMID 34469706, PMID 34933824, PMID 35300932, PMID 37703083, PMID 37963297, PMID 38096105, PMID 39581957
2009 (1), 2016 (1), 2017 (1), 2018 (1), K23HL175126 (1), R01HL124053 (1), R01HL171034 (1)